Truist raised the firm’s price target on Hinge Health (HNGE) to $62 from $48 and keeps a Buy rating on the shares, updating the firm’s model after the company’s Q2 results and guidance. The company’s robust outcomes data, extensive partner network, AI-enabled platform, and compelling economics create a flywheel of adoption, retention, and expansion, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health price target raised to $63 from $55 at Stifel
- Video: Disney, McDonald’s and Uber headline busy earnings slate
- Hinge Health price target raised to $64 from $42 at BofA
- Hinge Health price target raised to $57 from $46 at Morgan Stanley
- Hinge Health price target raised to $61 from $52 at Canaccord